85 completed. 85 Phase 1, 30 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 85 | Completed 85 |
| Phase 2 | 30 | Completed 30 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors AI-061 - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Completed | OncoC4, Inc. | 18 | 2023-07-11 | 2026-09-14 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) Evorpacept, Enfortumab Vedotin - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Completed | ALX Oncology Inc. | 36 | 2022-11-02 | 2025-07-25 |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) UGN-301, UGN-201, Gemcitabine - Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Completed | UroGen Pharma Ltd. | 51 | 2022-06-01 | 2026-01-14 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
| A Study of KF-0210 in Advanced Solid Tumors Patients KF-0210 tablets, 120 mg, KF-0210 tablets, 240 mg, KF-0210 tablets, 450 mg - Advanced Solid Tumor, Colorectal Cancer | Phase 1 | Completed | Keythera Pharmaceuticals (Australia) Pty Ltd | 14 | 2021-03-09 | 2024-09-24 |
| Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention Tranexamic acid - Urologic Diseases, Prostate Cancer | Phase 1 / Phase 2 | Completed | Fraser Health | 14 | 2021-03-01 | 2021-11-05 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors INCB106385, INCMGA00012 - Ovarian Cancer, Bladder Cancer | Phase 1 | Completed | Incyte Corporation | 54 | 2021-02-03 | 2025-07-11 |
| A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2, APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2 - Bladder Cancer | Phase 1 | Completed | Asieris Pharmaceuticals (AUS) Pty Ltd. | 12 | 2020-10-30 | 2021-06-30 |
| Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC CG0070, Nivolumab - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 21 | 2020-10-26 | 2026-02-27 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S QBS10072S - Astrocytoma, Brain Cancer | Phase 1 | Completed | Quadriga Biosciences, Inc. | 15 | 2020-07-20 | 2023-01-18 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies APR-246 (eprenetapopt) + Pembrolizumab - Bladder Cancer, Gastric Cancer | Phase 1 / Phase 2 | Completed | Aprea Therapeutics | 40 | 2020-06-25 | 2025-05-13 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Bosutinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung, Mesothelioma | Phase 1 | Completed | Nagla Abdel Karim | 6 | 2019-12-10 | 2022-06-14 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane - Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | NGM Biopharmaceuticals, Inc | 89 | 2019-10-16 | 2025-05-29 |
| First-in-human Study of S-588210 (S-488210+S-488211) S-488210, S-488211 - Lung Cancer, Head and Neck Cancer | Phase 1 | Completed | Shionogi | 10 | 2019-07-30 | 2022-01-26 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Avelumab, BCG - Bladder Cancer | Phase 1 / Phase 2 | Completed | University of Oklahoma | 18 | 2019-05-01 | 2024-02-14 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors TRK-950, Irinotecan, Leucovorin - Solid Tumor, Colorectal Cancer | Phase 1 | Completed | Toray Industries, Inc | 138 | 2019-04-26 | 2026-10-08 |
Showing 20 of 85. Sign in to see all of them.
Urinary Bladder Neoplasms (85) · Carcinoma, Non-Small-Cell Lung (25) · Ovarian Neoplasms (24) · Prostatic Neoplasms (21) · Breast Neoplasms (20) · Colorectal Neoplasms (20) · Lung Neoplasms (19) · Stomach Neoplasms (17) · Pancreatic Neoplasms (16) · Head and Neck Neoplasms (15) · Carcinoma, Renal Cell (14) · Esophageal Neoplasms (13) · Melanoma (13) · Kidney Neoplasms (10) · Squamous Cell Carcinoma of Head and Neck (10)
Female Urogenital Diseases (85) · Female Urogenital Diseases and Pregnancy Complications (85) · Male Urogenital Diseases (85) · Neoplasms by Site (85) · Urogenital Diseases (85) · Urogenital Neoplasms (83) · Urologic Diseases (83) · Urinary Bladder Diseases (82) · Urologic Neoplasms (81) · Neoplasms (79) · Neoplasms by Histologic Type (47) · Neoplasms, Glandular and Epithelial (42) · Carcinoma (39) · Genital Diseases (35) · Digestive System Diseases (34)
Gemcitabine (18) · Cisplatin (11) · Paclitaxel (9) · pembrolizumab (9) · Carboplatin (4) · Docetaxel (4) · Filgrastim (4) · Nivolumab (4) · Radiotherapy (4) · Albumin-Bound Paclitaxel (3) · Doxorubicin (3) · CDX 1307 (2) · Everolimus (2) · Irinotecan (2) · Lapatinib (2)
Memorial Sloan Kettering Cancer Center (9) · Incyte Corporation (3) · Celldex Therapeutics (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Ludwig Institute for Cancer Research (2) · M.D. Anderson Cancer Center (2) · Seagen Inc. (2) · TransThera Sciences (Nanjing), Inc. (2) · ALX Oncology Inc. (1) · Aprea Therapeutics (1) · Arcus Biosciences, Inc. (1) · Asieris Pharmaceuticals (AUS) Pty Ltd. (1) · Baylor College of Medicine (1) · Cadila Pharnmaceuticals (1) · Cancer Research UK (1)
United States (64) · United Kingdom (9) · Australia (7) · Denmark (5) · Spain (5) · Belgium (4) · Canada (4) · Italy (4) · Sweden (4) · France (3) · Germany (2) · Netherlands (2) · Switzerland (2) · China (1) · Hungary (1)
Dean F. Bajorin, MD (3) · Johann de Bono, Professor (2) · Adrian L. Harris, MD (1) · Aihua Edward Yen, MD (1) · Al B. Benson, MD, FACP (1) · Alan Pantuck, MD (1) · Ali Abdalvand, MD (1) · Amillal Bhat, MD (1) · Andreas Wicki, MD, PhD (1) · Anup Kundu, MD (1) · Ashish M. Kamat, MD (1) · B. R. Shrivastav, MD (1)
PMID 37496366, PMID 41044356, PMID 15928663, PMID 17409436, PMID 17452976, PMID 18245546, PMID 19100600, PMID 19636012, PMID 19706807, PMID 20407240, PMID 25366678, PMID 30552156, PMID 30745090, PMID 31320352, PMID 31796521, PMID 35012889, PMID 36084396, PMID 36600561, PMID 36669791, PMID 37082579, PMID 37469327, PMID 38155060, PMID 39462179, PMID 39521884, PMID 39762422, PMID 39886141, PMID 40830709, PMID 40973049, PMID 42201333
2017 (2), P50CA091846 (2), 2014 (1), P30CA016672 (1), P30CA023108 (1), P30CA138292 (1)